Bavarian Nordic A/S (BVNRY)
OTHER OTC:BVNRY
Want to see BVNRY full AI Analyst Report?
BVNRY Stock Chart & Stats
$10.36
-$0.28(-3.01%)
At close: 4:00 PM EST
$10.36
-$0.28(-3.01%)
Day’s Range― - ―
52-Week Range$7.82 - $12.54
Previous CloseN/A
Volume6.49K
Average Volume (3M)793.00
Market Cap
$2.28B
Enterprise Value$12.83B
Total Cash (Recent Filing)$3.33B
Total Debt (Recent Filing)$130.86M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding237,712,550
10 Day Avg. Volume0
30 Day Avg. Volume793
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.15
Price to Sales (P/S)2.49
P/FCF Ratio6.11
Enterprise Value/Market Cap5.64
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit4.56
Enterprise Value/Ebitda5.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthThe company’s extremely low leverage (debt-to-equity ~0.01) provides durable financial flexibility and reduces refinancing and interest risks. This balance-sheet strength supports capex, manufacturing scale-up, and bidding on government contracts without immediate capital strain.
Improving Profitability & MarginsMargin expansion in 2025 reflects better cost absorption and an improved product mix, producing more sustainable earnings. Stronger gross and net margins enhance cash flow convertibility and create ongoing capacity to fund R&D, commercial investment, and manufacturing resilience.
Government Procurement Revenue BaseLong-term procurement and stockpiling agreements with governments create structural demand that is less price-sensitive and often contract-backed. Such relationships provide a reliable baseline revenue stream and strategic positioning in biodefense and public-health preparedness markets.
Bears Say
Revenue VolatilityThe top line has been uneven — a notable decline in 2025 after flat sales in 2024 — indicating demand and order-timing sensitivity. Persistent revenue volatility undermines forecasting, can produce underutilized capacity, and makes multi-period planning and investment less predictable.
Uneven Cash-Flow Conversion HistoryDespite a strong 2025, the company’s cash-flow track record is uneven, with negative free cash flow in earlier years and weak conversion in 2023–2024. This episodic cash profile raises the risk of funding gaps for R&D, capex or inventory rebuilds absent consistent operating cash generation.
Order-Driven Revenue ConcentrationA meaningful share of sales depends on periodic government purchase orders and stockpiling cycles, creating lumpiness and timing risk. This concentration reduces revenue predictability and can amplify earnings swings when procurement pacing or budgets change.
Bavarian Nordic News
BVNRY FAQ
What was Bavarian Nordic A/S’s price range in the past 12 months?
Bavarian Nordic A/S lowest stock price was $7.82 and its highest was $12.54 in the past 12 months.
What is Bavarian Nordic A/S’s market cap?
Bavarian Nordic A/S’s market cap is $2.28B.
When is Bavarian Nordic A/S’s upcoming earnings report date?
Bavarian Nordic A/S’s upcoming earnings report date is May 13, 2026 which is in 12 days.
How were Bavarian Nordic A/S’s earnings last quarter?
Bavarian Nordic A/S released its earnings results on Mar 12, 2026. The company reported -$0.198 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.198.
Is Bavarian Nordic A/S overvalued?
According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued.
Does Bavarian Nordic A/S pay dividends?
Bavarian Nordic A/S pays a Notavailable dividend of $0.426 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here
What is Bavarian Nordic A/S’s EPS estimate?
Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bavarian Nordic A/S have?
Bavarian Nordic A/S has 237,712,550 shares outstanding.
What happened to Bavarian Nordic A/S’s price movement after its last earnings report?
Bavarian Nordic A/S reported an EPS of -$0.198 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.345%.
Which hedge fund is a major shareholder of Bavarian Nordic A/S?
Currently, no hedge funds are holding shares in BVNRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bavarian Nordic Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.68%
12-Months-Change
Fundamentals
Return on Equity
11.08%
Trailing 12-Months
Asset Growth
17.55%
Trailing 12-Months
Company Description
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
BVNRY Company Deck
BVNRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in both revenue and market expansion for Bavarian Nordic, especially in the Travel Health and Public Preparedness segments. However, there were some challenges related to the refinement of financial guidance and delays affecting the U.S. launch of the chikungunya vaccine.View all BVNRY earnings summariesTechnical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Apellis Pharmaceuticals
―
Immunovant
―
Kymera Therapeutics
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---